Obesity and Diabetes
TransTech Pharma, Inc. Obtains Exclusive License to Glucokinase Activator Program for the Treatment of Diabetes from Novo Nordisk
Published in Obesity and Diabetes Week, March 5th, 2007
TransTech Pharma and Novo Nordisk A/S (NYSE: NVO)(CSE: NVO) announced an agreement whereby TransTech has obtained an exclusive license from Novo Nordisk to its clinical glucokinase activator (GKA) program. Tests in a variety of mammalian species suggest that glucokinase activators can help people with diabetes control their glucose levels. Under the terms of the agreement, TransTech will obtain all rights worldwide to Novo Nordisk's GKA program including preclinical and clinical compounds, the latter with human data.
On 15 January, Novo Nordisk announced a decision to focus all its research and development resources on the company's growing pipeline of protein-based...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Bariatrics
Ceridian LifeWorks and Leade Health Launch Bariatric Surgery Health Coaching Service - Obesity
Arpida's lead antibiotic iclaprim is safe and well-tolerated in special populations with varying degrees of renal and hepatic impairment and obesity - Obesity
Manhattan Pharmaceuticals Completes Enrollment in Phase 2a Study of Oral Oleoyl-estrone for Obesity - Obesity and Diabetes
Open Rank - Diabetes and Obesity Research - Obesity and Diabetes
PALATIN TECHNOLOGIES, INC. REPORTS FISCAL YEAR 2007 SECOND QUARTER RESULTS; CONFERENCE CALL AND WEBCAST FEBRUARY 13, 2007 AT 10:00 A.M. EST - Obesity and Diabetes
ROAD Program Links Study of Type 2 Diabetes Risk Factors with Multiethnic School-Based Intervention - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
